Pr biosimlars volume pentration rate


Published on

Published in: Business, Technology
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Pr biosimlars volume pentration rate

  1. 1. The Penetration of Biosimilars in the US Will Vary Across Different Biological ClassesThe volume penetration of biosimilars in the US will strongly depend upon the complexity ofthe molecule, the patient pool that it caters and the extent of savings it brings to payers andprovidersIMARC Group, one of the world’s leading life science research and advisory firms, finds that asa result of their higher molecule complexity, higher cost of manufacturing and lower numberof biosimilar competitors (2-5 in case of biosimilars as against up to 9-10 in small moleculegenerics); the average volume penetration of biosimilars will be significantly lower than thatof small molecule generics. The study also expects the volume penetration of differentbiological classes to vary from one another depending upon the following factors: Biosimilars which are more complex will have a lower penetration compared to those that are less complex. Volume penetration would also depend upon how lucrative the branded biological drug is for biosimilar volume erosion. Drugs that have achieved blockbuster sales and show a good potential for future growth represent a good target for biosimilar companies. Payers and Providers are also expected to promote biosimilars which enable them to achieve substantial cost savings. Trends of in-market biosimilars show that penetration rates also depend upon the targeted indication and patient pool for biosimilar drugs. Drugs which are targeted towards more sensitive patients (i.e. children) are expected to have a lower penetration rate as physicians will not prescribe these drugs until they have significant long term safety and efficacy data. Similarly, indications where the benefits and side effects of the drug are not immediately visible and take a long time to identify (i.e. hormone deficiency) will have a lower share than indications where the side effects and benefits are easily visible (i.e. Anaemia). The penetration of various biosimilars would vary across different countries. The volume penetration of small molecule generics in the US has been found to be higher than that of major European markets. As a result, we expect biosimilar penetration in the US to be higher than major European markets.imarc© 1
  2. 2. IMARC’s new report entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” provides an analytical and statistical insight into the US biosimilar market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of six aspects of the US biosimilar market.Key Aspects Analyzed:Evaluating the Current Market Landscape of Biosimilars: Identification of currently marketed biosimilars and their historical performance Identifying the reasons for the slow uptake of currently marketed biosimilars Analyzing historical data to formulate conclusions on the future growth and market trends of biosimilarsEvaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars: Analyzing historical time series data on price, volume and sales erosion in the US & Europe Analyzing previous models and assumptions on price and volume erosion caused by biosimilars Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by small molecule generics Evaluating and comparing price, volume and sales erosion by biosimilars across various biological classesEvaluating the Market Potential of Biosimilars Across Various Molecules:Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa(Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog),Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), InterferonBeta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab(Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab(Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) andNatalizumab (Tysabri).imarc© 2
  3. 3. Focus of the Analysis for Each Molecule: Historical background and overview Historical brand sales Patent position Competing products Biosimilars in pipeline Brand and biosimilar sales forecastsEvaluating the Sales of Biosimilars across Various Indications:Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders andGrowth DeficiencyFocus of the Analysis for Each Indication: Historical brand sales Brand and biosimilar sales forecasts Indication wise breakup of moleculesEvaluating the Biosimilar Competitive Landscape: Identifying branded biological manufacturers that expect the highest amount of erosion from biosimilars Identifying biosimilar manufacturers and their pipelinesUnderstanding the Current Legislation on Biosimilars: An insight into the Biologics Price Competition and Innovation Act An insight into the key biosimilar issues that still remain unaddressed Interchangeability and Substitutability Data ExclusivityStatutory provisions for dealing with patent litigationsTo buy the complete report or to get a free sample, please contact:IMARC Group AsiaEmail: apac@imarcgroup.comPhone: +91-120-425-6531IMARC Group North Americaimarc© 3
  4. 4. Email: america@imarcgroup.comPhone: +1-631-791-1145To know more please visit: wordsBiosimilar market, biosimilar industry, follow-on biologics market, biogenerics market, us biosimilarmarket, biosimilar volume penetration rateimarc© 4